Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.22 USD
-0.14 (-5.93%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $2.23 +0.01 (0.45%) 5:54 PM ET
2-Buy of 5 2
F Value B Growth C Momentum D VGM
Checkpoint Therapeutics, Inc. (CKPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.33 | $27.00 | $8.00 | 676.69% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Checkpoint Therapeutics, Inc. comes to $18.33. The forecasts range from a low of $8.00 to a high of $27.00. The average price target represents an increase of 676.69% from the last closing price of $2.36.
Analyst Price Targets (3 )
Broker Rating
Checkpoint Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
6/24/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
6/22/2024 | Lake Street Capital Markets | Thomas Flaten | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $18.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.51 |
CKPT FAQs
Checkpoint Therapeutics, Inc. (CKPT) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Checkpoint Therapeutics, Inc. (CKPT) is $18.33. The current on short-term price targets is based on 2 reports.
The forecasts for Checkpoint Therapeutics, Inc. (CKPT) range from a low of $8 to a high of $27. The average price target represents a increase of $676.69 from the last closing price of $2.36.
The current UPSIDE for Checkpoint Therapeutics, Inc. (CKPT) is 676.69%
Based on short-term price targets offered by three analysts, the average price target for Checkpoint Therapeutics, Inc. comes to $18.33. The forecasts range from a low of $8.00 to a high of $27.00. The average price target represents an increase of 676.69% from the last closing price of $2.36.